Boehringer Ingelheim-backed Abalos tosses hat into packed oncolytic virus ring
Arenaviruses. They’re small, they’re packed with tiny stolen ribosomes that resemble grains of sand, they’re responsible for 300,000 to 500,000 human infections in West Africa each year, and, if a new German biotech has their way, they are going to one day treat tumors.
Abalos Therapeutics launched today with $12 million in funding to develop arenaviruses it hopes can be used in immunotherapy for cancer. The funding was co-led by Boehringer Ingelheim Venture Fund (BIVF) and Gruenderfonds Ruhr, with participation from NRW.BANK and High-Tech Gruenderfonds (HTGF).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.